Multifocal IOLs as presbyopia treatment

Article

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Implanting a multifocal intraocular lens (IOL) into the non-dominant eye is a promising treatment for presbyopic emmetropic patients, according to a study published in the February 2008 issue of Spektrum der Augenheilkunde.

Dr Thomas Neuhann of the Augenklinik am Marienplatz, Munich, Germany evaluated monocular implantation of a multifocal diffractive apodized IOL (SN60D3, AcrySof ReSTOR Natural; Alcon) as a rehabilitative treatment for emmetropic and presbyopic patients (n=24).

Six months after unilateral implantation, all patients were found to have bilateral uncorrected near vision of 20/30; 83% of patients recorded uncorrected distance vision of 20/20. Half of patients remained spectacle-dependent for intermediate vision. A questionnaire determined overall patient satisfaction of 79% for near, intermediate and distance vision. One patient requested IOL implantation in the second eye.

Dr Neuhann concluded that unilateral IOL implantation offers a viable treatment option for sufferers of emmetropia and presbyopia.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.